Gut Health & Inflammation
KPV and BPC-157 FDA Status
Understanding Legal Compliance for Licensed Practitioners
Gastrointestinal inflammation and inflammatory skin conditions represent a significant area of clinical interest. Licensed practitioners have explored peptide-based approaches based on preclinical research. This page documents where the peptides most discussed in this category actually stand—their legal status, their research foundation, and the compliance considerations clinics must understand before making any sourcing decisions.
Phoenix Meds Inc. is a peptide sourcing coordinator for licensed clinics. This page does something narrower: it documents regulatory status. This page documents what we found for each substance, with the source and the date.
HOW WE SUPPORT CLINICS
Phoenix Meds Regulatory Support Model
Regulatory Status Tracking
Current FDA position on each peptide, including Bulks List status, PCAC recommendations, and rulemaking activity as of September 2026.
Statutory Criteria Review
Analysis of the three statutory compounding pathways (USP/NF monograph, FDA-approved component, or Bulks List inclusion) and which peptides meet them.
Compliance Documentation
Support for clinics developing due diligence files showing regulatory research, legal counsel review, and informed decision-making.
Enforcement Risk, Explained
A plain-language account of FDA’s unapproved new drug authority and the state-level exposure most clinics overlook, organised so your own counsel can assess it. We are not lawyers and this is not a legal opinion.
Pharmacy Partner Network
For peptides WITH lawful pathways, we maintain vetted relationships with state-licensed 503A compounding pharmacies and FDA-registered 503B outsourcing facilities operating under CGMP requirements.
Ongoing Monitoring
Tracking of FDA Bulks Lists, PCAC recommendations, Federal Register rulemaking notices, and state board actions that affect peptide compounding status.
Critical Note for BPC-157 & KPV
Based on the federal sources reviewed in September 2026, we did not identify an applicable 503A or 503B compounding basis for BPC-157 or KPV from bulk drug substance. If a clinic asks about either substance, we document what the federal record shows and what we could not establish before any sourcing discussion. We provide regulatory information and documentation support only. Clinics should obtain advice from qualified legal counsel regarding any proposed arrangement.
REGULATORY SUPPORT DELIVERED
Clinic Benefits
✓ Clear Regulatory Status
Explicit, current FDA regulatory position on each peptide—not speculation or outdated information.
✓ Statutory Analysis
Transparent explanation of the applicable compounding criteria and how each substance compares with those criteria.✓ Enforcement Risk Clarity
Direct information about FDA’s unapproved new drug enforcement authority, recent warning letters, and state board actions against non-pharmacy entities.
✓ Documentation Support
Help developing compliance files that demonstrate due diligence and informed decision-making.
✓ Supplier Vetting
For substances where we identify an applicable compounding pathway, we review the relevant pharmacy or outsourcing-facility credentials and regulatory records. Where we do not identify an applicable pathway, supplier credentials do not by themselves establish one.
✓ Legal Counsel Ready
Information organised so clinics can brief their own counsel quickly, without rebuilding the research first.
Gut Inflammation and Inflammatory Skin Conditions
Intestinal barrier dysfunction and dysbiotic inflammatory responses are documented phenomena in gastroenterology and functional medicine practice. Similarly, certain inflammatory and reactive skin conditions present ongoing clinical management challenges where conventional options have limitations or tolerability concerns for individual patients.
Licensed practitioners in these spaces have explored peptide-based approaches based on preliminary laboratory research suggesting mechanism-level activity on inflammation regulation and barrier integrity. These explorations remain within the domain of prescriber discretion and patient-specific clinical judgment—which is a separate question from whether the material can lawfully be obtained at all.
The Two Peptides in This Category
BPC-157
What it is:
A 15-amino-acid peptide initially identified in gastric juice. Laboratory research has examined its relationship to mucosal barrier integrity, angiogenesis, and systemic anti-inflammatory signaling across multiple tissue contexts.
Research context:
Preclinical work spans gut barrier healing, systemic inflammation markers, and tissue repair across several animal models. The directly relevant human literature remains limited. Published studies document mechanism but not clinical efficacy.
FDA position:
BPC-157 holds no FDA approval. It was removed from the FDA’s Category 2 safety-risk list in April 2026 because the nomination was withdrawn, not because it was cleared for compounding. This removal changed nothing about legal status; the substance remains off both bulks lists and outside the FDA’s enforcement discretion policy. On 23–24 July 2026, the Pharmacy Compounding Advisory Committee considered BPC-157 for the 503A Bulks List. FDA’s own scientists recommended against it, citing insufficient safety, effectiveness, and characterization data. The committee voted to recommend it anyway, 8–6 with one abstention. That recommendation is non-binding; FDA must complete notice-and-comment rulemaking, and the agency is free to decline. No rulemaking has occurred as of September 2026. Based on the federal sources reviewed in September 2026, we did not identify an applicable basis under section 503A or 503B for compounding BPC-157 from bulk drug substance.
KPV
What it is:
A three-amino-acid fragment (lysine-proline-valine) derived from the C-terminal region of alpha-melanocyte-stimulating hormone (alpha-MSH). Laboratory research has focused on its role in anti-inflammatory signaling, specifically in intestinal and wound-healing contexts.
Research context:
The literature is modest — a few dozen papers, almost all preclinical, published from roughly 2000 onward and concentrated in murine colitis models and corneal epithelial healing. The FDA has stated that it identified no human exposure data for KPV via any route of administration.
FDA position:
KPV holds no FDA approval. It remains off both the 503A and 503B Bulks Lists and outside the FDA’s enforcement discretion policy. It is not a component of an FDA-approved drug product and has no applicable USP or NF monograph. On 23–24 July 2026, the Pharmacy Compounding Advisory Committee considered KPV for the 503A Bulks List. FDA’s own scientists recommended against it, citing insufficient safety, effectiveness, and characterization data. The committee voted to recommend KPV anyway by a vote of 8–6 with one abstention. That recommendation is non-binding; FDA must complete notice-and-comment rulemaking, and the agency is free to decline. No rulemaking has occurred as of September 2026. Based on the federal sources reviewed in September 2026, we did not identify an applicable basis under section 503A or 503B for compounding KPV from bulk drug substance.
Regulatory status current as of September 2026.
On the federal sources reviewed in September 2026, we did not identify an applicable 503A or 503B basis for compounding BPC-157 or KPV from bulk drug substance. The April 2026 removal from the Category 2 list was procedural (nominators withdrew their nominations) and changed nothing about legal status. The July 2026 PCAC recommendations are advisory and non-binding; FDA’s own scientists recommended against all seven substances reviewed, and the committee disagreed on six of them by narrow margins. Rulemaking has not occurred. Clinics must verify current FDA and state requirements before any sourcing decision. The status of peptides in the compounding pathway is actively evolving, and this page may become outdated; verify against FDA’s official bulks lists before acting.
The Current Research Landscape
Both BPC-157 and KPV emerge from a body of preclinical work examining small peptide fragments and their role in inflammation regulation. That work is genuine and documented in peer-reviewed literature. What remains absent is human clinical evidence establishing efficacy or optimal dosing for either peptide in any inflammatory condition.
No registered trial has produced published, peer-reviewed efficacy data for either compound. For KPV, a ClinicalTrials.gov search returns no registered studies at all. For BPC-157 the registry holds a Phase 1 safety and pharmacokinetic record from 2015 (NCT02637284, 42 healthy volunteers) that was never completed and never published, and FDA’s July 2026 review identified only two human studies overall, both by rectal enema and both limited to two weeks. The pathway from preclinical mechanism to clinical application has not been completed for either. This means that:
- Human safety data is confined to small, short studies using routes of administration that are not the ones clinics use. FDA has said it cannot characterise the safety profile from what exists.
- Effective dosing ranges are not established by clinical trials.
- Candidate patient populations and contraindications are not defined.
- Mechanism in human tissue cannot be confirmed.
- For BPC-157, FDA has separately raised immunogenicity risk and inadequate physicochemical characterisation — meaning identity, purity and quality attributes are not reliably established even at the raw material level.
The limited human evidence described above does not establish an evidence-based clinical protocol for either substance. Questions of treatment, prescribing and standard of care belong to the licensed clinician and are separate from the federal compounding analysis on this page.
Why Clinics Have Explored These Peptides
Despite the regulatory and evidence limitations outlined above, these peptides have gained attention in clinic settings because:
- Mechanism is plausible. The preclinical literature is real, and the proposed pathways—barrier integrity, anti-inflammatory signaling, cell migration—address recognized clinical challenges.
- Conventional alternatives have limits. For certain patients, standard anti-inflammatory strategies present tolerability or efficacy ceilings, making exploration of mechanism-based alternatives rationally defensible.
- Off-label prescribing is familiar territory. Practitioners are used to broad discretion in prescribing approved drugs off-label. Off-label prescribing authority does not itself create a federal compounding pathway for a bulk drug substance. Prescribing authority and compounding eligibility are separate questions.
- Patient demand exists. Individuals with functional GI or dermatologic concerns actively seek peptide options they have encountered in wellness and medical literature.
None of the above is a recommendation to use these compounds. Phoenix Meds does not determine whether a preparation is lawful. We document what the FDA record shows so the clinic and its counsel can. We publish this page so clinics can see the regulatory position in full, and hand it to their own counsel, before anyone quotes them a price.
What to Verify Before Any Sourcing Decision
Because neither BPC-157 nor KPV has an approved reference product or established compounding pathway, the burden of quality assurance falls almost entirely on documentation and supplier vetting. Here’s what clinics should prioritize:
Documentation and Certificate of Analysis
A third-party certificate of analysis tied to the specific lot being purchased is essential. It should confirm identity via a named analytical method, report purity, and include sterility and endotoxin testing for injectable formulations. Generic certificates are insufficient; verify the lot number on the certificate against the vial. A certificate of analysis addresses product testing and identity; it does not itself establish a federal compounding pathway.
Supplier Transparency on Legal Basis
Ask your supplier directly: what is the legal basis they rely on for compounding this peptide? Request the answer in writing. For BPC-157 and KPV specifically, under section 503A, compounding is permitted only if the bulk substance has a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List. Neither peptide meets any of these three conditions as of September 2026. A supplier claiming to operate under one of these pathways should be asked to identify which specific criterion they satisfy and to provide supporting documentation. Based on the federal sources reviewed, we did not identify an applicable 503A or 503B basis for these substances. A supplier relying on a different basis should identify that basis and the supporting regulatory record in writing so it can be evaluated independently by the clinic, pharmacy and qualified counsel.
Research-Use vs. Clinical-Use Material
Most BPC-157 and KPV in circulation move as “research use only, not for human consumption” material. Important: The “research use only” label does not provide legal protection. On 17 June 2026, FDA issued a warning letter to a peptide wholesaler citing misbranded unapproved new drugs under FD&C sections 505(a), 301(d), and 201(g)(1), and explicitly stated that the company’s “research use only” disclaimers did not shield it from enforcement. The trigger was ordinary benefit copy. RUO labeling should not be treated as a regulatory pathway for clinical use. Do not rely on RUO labeling as a legal pathway. Clarify the actual intended use and regulatory basis with your supplier in writing before ordering.
Pharmacy Credentials
Verify that your sourcing partner is a state-licensed 503A compounding pharmacy or an FDA-registered 503B outsourcing facility. Confirm these credentials independently; “we work with FDA” does not confirm registration, and “FDA-approved pharmacy” is not a term FDA uses, and FDA does not issue GMP certificates to anyone. A state pharmacy license, or registration as a 503B outsourcing facility, does not by itself establish that a particular bulk drug substance may be used in compounding. For these two peptides, the facility credential does not by itself establish an applicable bulk-substance basis.
Regulatory Position and Phoenix Meds Coordination Policy
Sourcing Position (September 2026)
As of September 2026, we have not identified a basis for compounded drug products made from BPC-157- or KPV-related bulk drug substances to qualify for the federal exemptions under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
In July 2026, FDA’s Pharmacy Compounding Advisory Committee considered BPC-157, BPC-157 acetate, KPV and KPV acetate for inclusion on the 503A Bulks List. The committee voted to recommend adding them. That recommendation was advisory and nonbinding. It did not itself add any of these substances to the 503A Bulks List or make products containing them FDA-approved.
As of September 2026, FDA had not completed rulemaking adding these substances to the 503A Bulks List. We therefore disclose the current status to the clinic before any sourcing discussion and re-check the applicable FDA records if the matter progresses.
What this means for your practice:
Phoenix Meds can provide regulatory information and regulatory due-diligence support, but we do not coordinate supply where we cannot verify an applicable federal compounding basis. We can help your practice:
- Review the current FDA regulatory status of a bulk drug substance
- Understand the relevant 503A and 503B statutory criteria
- Document the regulatory sources consulted during due diligence
- Review and independently check supplier representations
- Organize relevant materials for review by your legal counsel
- Monitor FDA Bulks Lists, Federal Register notices and relevant state-board activity
We maintain this page because the July 2026 committee vote has sometimes been described as FDA approval. It was not. The committee recommended inclusion, but an advisory vote does not amend the 503A Bulks List and does not constitute approval of a drug product. If FDA publishes a proposed or final rule affecting either substance, we will review the notice and update this page. Phoenix Meds does not provide legal or medical advice. Clinics should obtain advice from qualified healthcare and legal professionals regarding any proposed treatment or compounding arrangement.
Verify This Yourself
FDA — Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026 (substances reviewed and meeting materials)
FDA briefing document — BPC-157 free base and acetate, PCAC July 2026 (agency recommendation against inclusion)
FDA — Bulk drug substances used in compounding under section 503A (503A bulks list and the Category 1/2/3 interim policy)
FDA — 503B Bulk Drug Substances List (five substances, none of them peptides)
FDA warning letter — Wholesale Peptide, 17 June 2026 (“research use only” labelling and intended use)
Holland & Knight — FDA Advisory Committee Endorses Compounding of Certain Peptides (August 2026 legal analysis)
Frier Levitt — Peptides Under the Microscope: FDA and State Enforcement Trends (state board actions against non-pharmacy entities)
Related Clinic Resources
KPV Peptide: Clinic Coordination & Documentation Guide:
Deep dive into KPV’s research status, current FDA position, and vetting criteria for suppliers.
BPC-157 Versus TB-500 for Licensed Clinics:
Comparative guide to tissue repair peptides with regulatory status and sourcing considerations.
Choosing a Reliable Medical Injectable Supplier:
Comprehensive vetting framework applicable to all peptide sourcing.
Storage and Handling of Lyophilized Peptides:
Best practices for maintaining peptide integrity from arrival through administration.
Growth Hormone Secretagogue Peptides: Clinic Guide:
Comprehensive guide to secretagogue peptides with regulatory and sourcing information.
Epithalon & Thymosin Alpha-1: Sourcing Guide:
Related peptide sourcing guide covering regulatory status and clinic considerations.
Disclaimer and regulatory scope:
This page is regulatory information for licensed clinics, compiled from public FDA materials. It is not medical or legal advice, and not a determination that any product or preparation is lawful.
On the federal sources reviewed in September 2026 we did not identify a 503A or 503B basis permitting BPC-157 or KPV to be compounded from bulk. Both sit in the nominated-but-withdrawn table on FDA’s safety-risks page. That is our finding on those sources at that time, not a legal conclusion.
State pharmacy law and medical practice acts apply on top. For how 503A and 503B differ and what the bulks lists are, see our Legal & Regulatory Status Overview. Work with counsel in your state.
Phoenix Meds Inc. is not a pharmacy, clinic, prescriber or medical provider, and we do not dispense. We coordinate sourcing between licensed clinics and licensed pharmacies. The pharmacy or outsourcing facility prepares, dispenses and ships; any clinical decision rests with the prescriber. Last reviewed: September 2026.